{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/FDMT/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-10T21:10:28.650Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":4096,"canonical_name":"4D Molecular Therapeutics, Inc.","cik":"0001650648","uei":null,"lei":null,"duns":null,"ticker":"FDMT"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":36},"count":36,"timeline":[{"ts":"2026-07-20","kind":"sec.filing","form_type":"8-K","title":"8-K — 4D Molecular Therapeutics, Inc. — 2026-07-20","url_slug":"/sec/cik-0001650648/8-k/0001193125-26-308409","accession_number":"0001193125-26-308409","importance":35},{"ts":"2026-07-14","kind":"sec.filing","form_type":"4","title":"4 — 4D Molecular Therapeutics, Inc. — 2026-07-14","url_slug":"/sec/cik-0001650648/4/0001834021-26-000004","accession_number":"0001834021-26-000004","importance":30},{"ts":"2026-07-10","kind":"sec.insider.s","reporter":"Kirn David","title":"See Remarks","shares":15283,"price_per_share":12.0107,"usd_value":183560,"security_title":"Common Stock","importance":35.1835595281},{"ts":"2026-07-10","kind":"sec.insider.s","reporter":"Kirn David","title":"See Remarks","shares":442,"price_per_share":12.8355,"usd_value":5673,"security_title":"Common Stock","importance":35.005673291},{"ts":"2026-07-10","kind":"sec.filing","form_type":"144","title":"144 — 4D Molecular Therapeutics, Inc. — 2026-07-10","url_slug":"/sec/cik-0001650648/144/0001958244-26-000446","accession_number":"0001958244-26-000446","importance":30},{"ts":"2026-07-09","kind":"sec.form144","reporter":"David Kirn","title":"Officer","shares":42608,"usd_value":549217,"security_title":"Class A Common","approx_sale_date":"2026-07-09","accession_number":"0001958244-26-000444","importance":40.109843424},{"ts":"2026-07-09","kind":"sec.insider.s","reporter":"Kirn David","title":"See Remarks","shares":42608,"price_per_share":12.8656,"usd_value":548177,"security_title":"Common Stock","importance":35.5481774848},{"ts":"2026-07-09","kind":"sec.filing","form_type":"144","title":"144 — 4D Molecular Therapeutics, Inc. — 2026-07-09","url_slug":"/sec/cik-0001650648/144/0001958244-26-000444","accession_number":"0001958244-26-000444","importance":30},{"ts":"2026-07-02","kind":"sec.filing","form_type":"4","title":"4 — 4D Molecular Therapeutics, Inc. — 2026-07-02","url_slug":"/sec/cik-0001650648/4/0001920738-26-000004","accession_number":"0001920738-26-000004","importance":30},{"ts":"2026-06-30","kind":"sec.form144","reporter":"SCOTT BIZILY","title":"Officer","shares":6566,"usd_value":84570,"security_title":"COMMON","approx_sale_date":"2026-06-30","accession_number":"0001950047-26-006669","importance":40.016914016},{"ts":"2026-06-30","kind":"sec.insider.s","reporter":"Bizily Scott","title":"Chief Legal Officer","shares":6566,"price_per_share":14,"usd_value":91924,"security_title":"Common Stock","importance":35.091924},{"ts":"2026-06-30","kind":"sec.filing","form_type":"144","title":"144 — 4D Molecular Therapeutics, Inc. — 2026-06-30","url_slug":"/sec/cik-0001650648/144/0001950047-26-006669","accession_number":"0001950047-26-006669","importance":30},{"ts":"2026-06-30","kind":"sec.insider.m","reporter":"Bizily Scott","title":"Chief Legal Officer","shares":5752,"price_per_share":6.49,"usd_value":37330,"security_title":"Common Stock","importance":15.03733048},{"ts":"2026-06-30","kind":"sec.insider.m","reporter":"Bizily Scott","title":"Chief Legal Officer","shares":814,"price_per_share":4.14,"usd_value":3370,"security_title":"Common Stock","importance":15.00336996},{"ts":"2026-06-29","kind":"sec.filing","form_type":"8-K","title":"8-K — 4D Molecular Therapeutics, Inc. — 2026-06-29","url_slug":"/sec/cik-0001650648/8-k/0001193125-26-286880","accession_number":"0001193125-26-286880","importance":35},{"ts":"2026-06-25","kind":"sec.filing","form_type":"4","title":"4 — 4D Molecular Therapeutics, Inc. — 2026-06-25","url_slug":"/sec/cik-0001650648/4/0001920738-26-000002","accession_number":"0001920738-26-000002","importance":30},{"ts":"2026-06-23","kind":"sec.insider.s","reporter":"Bizily Scott","title":"Chief Legal Officer","shares":9810,"price_per_share":12,"usd_value":117720,"security_title":"Common Stock","importance":35.11772},{"ts":"2026-06-23","kind":"sec.filing","form_type":"144","title":"144 — 4D Molecular Therapeutics, Inc. — 2026-06-23","url_slug":"/sec/cik-0001650648/144/0001950047-26-006432","accession_number":"0001950047-26-006432","importance":30},{"ts":"2026-06-23","kind":"sec.filing","form_type":"4","title":"4 — 4D Molecular Therapeutics, Inc. — 2026-06-23","url_slug":"/sec/cik-0001650648/4/0001834021-26-000002","accession_number":"0001834021-26-000002","importance":30},{"ts":"2026-06-23","kind":"sec.insider.m","reporter":"Bizily Scott","title":"Chief Legal Officer","shares":9810,"price_per_share":4.14,"usd_value":40613,"security_title":"Common Stock","importance":15.0406134},{"ts":"2026-06-22","kind":"sec.form144","reporter":"David Kirn","title":"Officer","shares":114746,"usd_value":1195653,"security_title":"Class A Common","approx_sale_date":"2026-06-22","accession_number":"0001958244-26-000396","importance":40.239130664},{"ts":"2026-06-22","kind":"sec.insider.s","reporter":"Kirn David","title":"See Remarks","shares":114746,"price_per_share":10.4653,"usd_value":1200851,"security_title":"Common Stock","importance":36.2008513138},{"ts":"2026-06-22","kind":"sec.filing","form_type":"8-K","title":"8-K — 4D Molecular Therapeutics, Inc. — 2026-06-22","url_slug":"/sec/cik-0001650648/8-k/0001193125-26-277563","accession_number":"0001193125-26-277563","importance":35},{"ts":"2026-06-22","kind":"sec.filing","form_type":"144","title":"144 — 4D Molecular Therapeutics, Inc. — 2026-06-22","url_slug":"/sec/cik-0001650648/144/0001958244-26-000396","accession_number":"0001958244-26-000396","importance":30},{"ts":"2026-06-18","kind":"sec.filing","form_type":"4","title":"4 — 4D Molecular Therapeutics, Inc. — 2026-06-18","url_slug":"/sec/cik-0001650648/4/0001193125-26-276160","accession_number":"0001193125-26-276160","importance":30},{"ts":"2026-06-18","kind":"sec.filing","form_type":"4","title":"4 — 4D Molecular Therapeutics, Inc. — 2026-06-18","url_slug":"/sec/cik-0001650648/4/0001193125-26-276163","accession_number":"0001193125-26-276163","importance":30},{"ts":"2026-06-02","kind":"sec.filing","form_type":"4","title":"4 — 4D Molecular Therapeutics, Inc. — 2026-06-02","url_slug":"/sec/cik-0001650648/4/0001193125-26-253740","accession_number":"0001193125-26-253740","importance":30},{"ts":"2026-06-01","kind":"sec.form144","reporter":"David Kirn","title":"Officer","shares":1922,"usd_value":18663,"security_title":"Class A Common","approx_sale_date":"2026-06-01","accession_number":"0001958244-26-000339","importance":40.003732524},{"ts":"2026-06-01","kind":"sec.insider.s","reporter":"Kirn David","title":"See Remarks","shares":1922,"price_per_share":10.0197,"usd_value":19258,"security_title":"Common Stock","importance":35.0192578634},{"ts":"2026-06-01","kind":"sec.filing","form_type":"144","title":"144 — 4D Molecular Therapeutics, Inc. — 2026-06-01","url_slug":"/sec/cik-0001650648/144/0001958244-26-000339","accession_number":"0001958244-26-000339","importance":30},{"ts":"2026-05-15","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — 4D Molecular Therapeutics, Inc. — 2026-05-15","url_slug":"/sec/cik-0001650648/schedule-13g-a/0000921895-26-001391","accession_number":"0000921895-26-001391","importance":30},{"ts":"2026-05-13","kind":"sec.filing","form_type":"EFFECT","title":"EFFECT — 4D Molecular Therapeutics, Inc. — 2026-05-13","url_slug":"/sec/cik-0001650648/effect/9999999995-26-001626","accession_number":"9999999995-26-001626","importance":30},{"ts":"2026-05-12","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — 4D Molecular Therapeutics, Inc. — 2026-05-12","url_slug":"/sec/cik-0001650648/schedule-13g/0000093751-26-000197","accession_number":"0000093751-26-000197","importance":55},{"ts":"2026-05-12","kind":"sec.13dg","reporter":"4D Molecular Therapeutics, Inc.","shares":2707875,"percent_of_class":5.3,"security_title":"SCHEDULE 13G","accession_number":"0000093751-26-000197","excerpt":null,"importance":55},{"ts":"2026-05-11","kind":"sec.filing","form_type":"CORRESP","title":"CORRESP — 4D Molecular Therapeutics, Inc. — 2026-05-11","url_slug":"/sec/cik-0001650648/corresp/0001193125-26-216930","accession_number":"0001193125-26-216930","importance":30},{"ts":"2026-05-08","kind":"sec.filing","form_type":"UPLOAD","title":"UPLOAD — 4D Molecular Therapeutics, Inc. — 2026-05-08","url_slug":"/sec/cik-0001650648/upload/0000000000-26-004734","accession_number":"0000000000-26-004734","importance":30}]}